Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Centogene NV
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
- Digital Health
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools